Last reviewed · How we verify
COVID19 convalescent plasma infusion
COVID-19 convalescent plasma infusion transfers antibodies and immune factors from recovered patients to provide passive immunotherapy against SARS-CoV-2.
COVID-19 convalescent plasma infusion transfers antibodies and immune factors from recovered patients to provide passive immunotherapy against SARS-CoV-2. Used for COVID-19 (severe or life-threatening disease), COVID-19 (hospitalized patients).
At a glance
| Generic name | COVID19 convalescent plasma infusion |
|---|---|
| Sponsor | Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno |
| Drug class | Passive immunotherapy / Convalescent plasma |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The infusion contains polyclonal antibodies and other immune components from donors who have recovered from COVID-19, which neutralize the virus and enhance immune clearance in infected recipients. This passive immunotherapy approach aims to reduce viral load, prevent disease progression, and improve clinical outcomes in hospitalized COVID-19 patients, particularly those with severe disease or immunocompromised status.
Approved indications
- COVID-19 (severe or life-threatening disease)
- COVID-19 (hospitalized patients)
Common side effects
- Transfusion-related acute lung injury (TRALI)
- Allergic reactions
- Transfusion-associated circulatory overload (TACO)
- Fever
Key clinical trials
- Analysis of Coronavirus Disease 19 (COVID-19) Convalescent Plasma
- Efficacy of Reinforcing Standard Therapy in COVID-19 Patients With Repeated Transfusion of Convalescent Plasma (NA)
- Early High-Titre Convalescent Plasma in Clinically Vulnerable Individuals With Mild COVID-19 (PHASE3)
- Convalescent Plasma for Early Treatment of COVID-19 (PHASE2)
- Therapeutic Plasma Exchange Followed by Convalescent Plasma Transfusion in Severe and Critically Ill COVID-19 Patients (NA)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial (PHASE3)
- Efficacy and Safety of Convalescent Plasma in Treating COVID-19 Hospitalized Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: